Africa: Malaria Vaccine Becomes First to Achieve WHO-specified 75% Efficacy Goal

[Oxford University] Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up.


Leave a Reply

Your email address will not be published. Required fields are marked *